Måndag 16 Mars | 09:09:57 Europe / Stockholm

Svenska | English

IO Biotech, Inc.

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2026-01-30 14:05:00 IO Biotech Provides Corporate Update 0,29 USD | -8,28%

2026-01-21 11:30:00 IO Biotech Announces Exploration of Strategic Alternatives 0,21 USD | -59,74%

2025-12-15 22:05:00 IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications 0,71 USD | -12,54%

2025-11-26 16:46:51 IO Biotech Announces Participation in Upcoming December Investor Conferences 0,73 USD | +0,94%

2025-11-14 14:05:00 IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights 0,83 USD | +1,71%

2025-11-12 14:30:00 IO Biotech Announces Participation in Upcoming Investor Conferences 0,82 USD | -6,00%

2025-11-07 15:00:00 IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) 0,90 USD | +6,96%

2025-10-20 08:30:00 IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 0,82 USD | +25,18%

2025-09-29 13:05:00 IO Biotech Provides Update Following Pre-BLA Meeting with FDA 0,37 USD | -76,89%

2025-09-23 14:05:00 IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025 1,60 USD | +7,38%

2025-09-04 14:05:00 IO Biotech Announces Participation in Upcoming Investor Conferences 1,78 USD | +1,71%

2025-08-10 14:00:00 IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

2025-05-20 14:05:00 IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference 1,03 USD | 0,00%

2025-05-14 14:05:00 IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

2025-04-26 21:05:00 IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

2025-04-25 19:00:00 IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 0,96 USD | +4,03%

2025-03-25 21:35:00 IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting 1,17 USD | +17,00%

2025-03-04 22:17:04 IO Biotech Reports 2024 Business Highlights 0,91 USD | +5,91%

2025-02-23 18:07:39 IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

2025-02-20 14:05:00 IO Biotech to Present at the 45th Annual Cowen Health Care Conference 1,11 USD | +11,00%

2025-02-04 14:05:00 IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate 0,95 USD | +6,74%

2025-01-09 14:05:00 IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

2024-12-20 14:05:00 IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank 0,77 USD | +1,43%

2024-11-12 13:05:00 IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights 0,93 USD | -11,68%

2024-11-11 22:05:00 IO Biotech Announces Participation in Upcoming Investor Conferences 1,05 USD | -4,55%

2024-11-07 16:00:00 IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study 1,23 USD | +6,03%

2024-10-04 15:00:00 IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting 1,15 USD | +13,86%

2024-09-14 08:30:00 IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

2024-08-30 22:05:00 IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma 1,50 USD | -2,60%

2024-08-26 22:05:00 IO Biotech Announces Participation in Upcoming Investor Conferences 1,57 USD | -4,27%

2024-08-13 13:05:00 IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights 1,53 USD | +17,69%

2024-07-25 22:05:00 IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 1,34 USD | -0,74%

2024-05-23 14:30:00 IO Biotech to Present at Jefferies Global Healthcare Conference 1,32 USD | -0,75%

2024-05-14 13:55:00 IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights 1,44 USD | +2,13%

2024-04-24 22:30:00 IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting 1,46 USD | -0,68%

2024-04-09 18:00:00 IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 1,61 USD | +4,55%

2024-04-05 14:30:00 IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer 1,58 USD | -3,66%

2024-03-06 22:11:01 IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting 1,66 USD | +2,47%

2024-03-05 22:40:01 IO Biotech Announces 2023 Fourth-Quarter and Year-End Results 1,62 USD | -3,57%

2024-02-26 22:05:00 IO Biotech to Present at 44th Annual Cowen Health Care Conference 1,55 USD | +2,65%

2023-12-21 14:30:00 IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial 1,46 USD | -1,35%

2023-11-13 14:12:16 IO Biotech Announces 2023 Third Quarter Results 0,95 USD | +2,30%

2023-11-08 22:30:00 IO Biotech Announces Participation in Upcoming Investor Conferences 0,95 USD | -2,73%

2023-11-01 13:30:00 IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting 0,87 USD | +1,30%

2023-10-03 22:30:00 IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting 1,51 USD | +10,22%

2023-09-12 14:05:00 IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer 1,45 USD | -13,20%

2023-09-06 14:35:00 IO Biotech Announces Participation in Upcoming Investor Conferences 1,75 USD | -4,37%

2023-08-11 14:30:00 IO Biotech Announces 2023 Second Quarter Results 1,83 USD | 0,00%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

IO Biotech, Inc.

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden